New potential beneficial effects of actein, a triterpene glycoside isolated from Cimicifuga species, in breast cancer treatment
Publication in refereed journal

Full Text

Times Cited
Altmetrics Information

Other information
AbstractActein is a triterpene glycoside isolated from the rhizomes of Cimicifuga foetida (Chinese herb “shengma”) which could inhibit the growth of breast cancer cells. Nevertheless, the effect of actein on angiogenesis, which is an essential step for tumor growth and metastasis, has never been reported. Hence, this study aimed to investigate the in vitro and in vivo effects of actein on angiogenesis using human microvascular endothelial cells (HMEC-1), matrigel plug and tumor-bearing mouse models. Our results showed that actein significantly inhibited the proliferation, reduced the migration and motility of endothelial cells, and it could suppress the protein expressions of VEGFR1, pJNK and pERK, suggesting that JNK/ERK pathways were involved. In vivo results showed that oral administration of actein at 10 mg/kg for 7 days inhibited blood vessel formation in the growth factor-containing matrigel plugs. Oral actein treatments (10–15 mg/kg) for 28 days resulted in decreasing mouse 4T1 breast tumor sizes and metastasis to lungs and livers. The apparent reduced angiogenic proteins (CD34 and Factor VIII) expressions and down-regulated metastasis-related VEGFR1 and CXCR4 gene expressions were observed in breast tumors. Our novel findings provide insights into the use of actein for development of anti-angiogenic agents for breast cancer.
All Author(s) ListGrace Gar-Lee Yue, Sida Xie, Julia Kin-Ming Lee, Hin-Fai Kwok, Si Gao, Yin Nian, Xiao-Xiao Wu, Chun-Kwok Wong, Ming-Hua Qiu, Clara Bik-San Lau
Journal nameScientific Reports
Volume Number6
PublisherNature Publishing Group: Open Access Journals - Option C / Nature Publishing Group
LanguagesEnglish-United States

Last updated on 2021-16-09 at 00:55